Skip navigation
Skip navigation

Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study

Lidbury, Brett; Kita, Badia; Lewis, Don; Hayward, Susan; Ludlow, Helen; Hedger, Mark P; de Kretser, David M

Description

BACKGROUND: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available. METHODS: A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted....[Show more]

dc.contributor.authorLidbury, Brett
dc.contributor.authorKita, Badia
dc.contributor.authorLewis, Don
dc.contributor.authorHayward, Susan
dc.contributor.authorLudlow, Helen
dc.contributor.authorHedger, Mark P
dc.contributor.authorde Kretser, David M
dc.date.accessioned2021-05-05T04:46:17Z
dc.date.available2021-05-05T04:46:17Z
dc.identifier.issn1479-5876
dc.identifier.urihttp://hdl.handle.net/1885/231453
dc.description.abstractBACKGROUND: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available. METHODS: A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18-65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals. RESULTS: Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma. CONCLUSION: Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients.
dc.description.sponsorshipThe Alison Hunter Memorial Foundation (AHMF), National Health and Medical Research Council of Australia, and the Victorian Government’s Operational Infrastructure Support Program. The funding bodies acknowledged above had no input into the design or conduct of this study
dc.format.mimetypeapplication/pdf
dc.language.isoen_AU
dc.publisherBioMed Central
dc.rights© The Author(s) 2017
dc.rights.uri(http://creativecommons.org/ publicdomain/zero/1.0/
dc.sourceJournal of Translational Medicine
dc.source.urihttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1161-4
dc.subjectMyalgic encephalomyelitis (ME)
dc.subjectChronic fatigue syndrome (CFS)
dc.subjectBiomarker
dc.subjectActivins
dc.subjectDiagnosis
dc.titleActivin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume15
dc.date.issued2017
local.identifier.absfor110316 - Pathology
local.identifier.absfor110302 - Clinical Chemistry (diagnostics)
local.identifier.absfor111706 - Epidemiology
local.identifier.ariespublicationu4102339xPUB124
local.publisher.urlhttps://translational-medicine.biomedcentral.com
local.type.statusPublished Version
local.contributor.affiliationLidbury, Brett, College of Health and Medicine, ANU
local.contributor.affiliationKita, Badia, Paranta Biosciences Limited, Caulfield North, VIC, 3161, Australia
local.contributor.affiliationLewis, Don, CFS Discovery
local.contributor.affiliationHayward , Susan , The Hudson Medical Research Institute, Monash University
local.contributor.affiliationLudlow, Helen, Centre for Proteins and Peptides, School of Life Sciences, Oxford Brookes University
local.contributor.affiliationHedger , Mark P , The Hudson Medical Research Institute, Monash University,
local.contributor.affiliationde Kretser, David M, Monash University
local.bibliographicCitation.issue1
local.bibliographicCitation.startpage60
local.bibliographicCitation.lastpage60
local.identifier.doi10.1186/s12967-017-1161-4
local.identifier.absseo920408 - Health Status (e.g. Indicators of Well-Being)
local.identifier.absseo920199 - Clinical Health (Organs, Diseases and Abnormal Conditions) not elsewhere classified
local.identifier.absseo920203 - Diagnostic Methods
dc.date.updated2020-11-23T10:09:36Z
local.identifier.scopusID2-s2.0-85015428370
local.identifier.thomsonID000396942100002
dcterms.accessRightsopen access
dc.provenance7. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.rights.licenseCreative Commons Attribution licence
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Lidbury_Activin_B_is_a_novel_biomarker_2017.pdf838.14 kBAdobe PDFThumbnail


This item is licensed under a Creative Commons License Creative Commons

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator